Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Shire Plc Ads (SHPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,706,176
  • Shares Outstanding, K 305,280
  • Annual Sales, $ 15,161 M
  • Annual Income, $ 4,272 M
  • 60-Month Beta 0.87
  • Price/Sales 3.48
  • Price/Cash Flow N/A
  • Price/Book 1.46
  • Price/Earnings ttm 11.21
  • Earnings Per Share ttm 15.36
  • Most Recent Earnings 3.64 on 11/01/18
  • Next Earnings Date 02/13/19
  • Annual Dividend & Yield 0.34 (0.00%)
  • Most Recent Dividend 0.168 on 09/06/18
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 3.78
  • Number of Estimates 6
  • High Estimate 3.87
  • Low Estimate 3.67
  • Prior Year 3.98
  • Growth Rate Est. (year over year) -5.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
165.29 +8.42%
on 12/18/18
181.22 -1.11%
on 01/04/19
+7.70 (+4.49%)
since 12/04/18
3-Month
165.29 +8.42%
on 12/18/18
182.47 -1.79%
on 11/12/18
+2.35 (+1.33%)
since 10/04/18
52-Week
123.73 +44.83%
on 02/09/18
182.47 -1.79%
on 11/12/18
+21.91 (+13.93%)
since 01/04/18

Most Recent Stories

More News
OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019

OrbiMed Advisors LLC ("OrbiMed") has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. ("ISS") and the management of Takeda Pharmaceutical Company...

SHPG : 179.20 (+4.10%)
OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019

OrbiMed Advisors LLC ("OrbiMed") has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. ("ISS") and the management of Takeda Pharmaceutical Company...

SHPG : 179.20 (+4.10%)
OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019

OrbiMed Advisors LLC ("OrbiMed") has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. ("ISS") and the management of Takeda Pharmaceutical Company...

SHPG : 179.20 (+4.10%)
OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019

OrbiMed Advisors LLC ("OrbiMed") has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. ("ISS") and the management of Takeda Pharmaceutical Company...

SHPG : 179.20 (+4.10%)
OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019

OrbiMed Advisors LLC ("OrbiMed") has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. ("ISS") and the management of Takeda Pharmaceutical Company...

SHPG : 179.20 (+4.10%)
OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019

OrbiMed Advisors LLC ("OrbiMed") has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. ("ISS") and the management of Takeda Pharmaceutical Company...

SHPG : 179.20 (+4.10%)
Dry Eye Syndrome Treatment Market Size, Key Manufacturers, Application, Type, End-user, Forecast to 2028

Dry eye syndrome also known as keratoconjunctivitis sicca (KCS) is a condition when an individual suffers from dry eyes. The symptoms of dry eye syndrome include irritation, redness, discharge, blurred...

VRX.TO : 30.80 (-3.33%)
ABT : 83.53 (+0.13%)
AGN : 125.66 (+4.16%)
SHPG : 179.20 (+4.10%)
Retinal Pharmaceuticals Market – Detailed Analysis of Current Industry Figures with Forecasts Growth By 2024

The Global Retinal Pharmaceuticals Market 2019-2024 Renders deep perception of the Market Segment by Regions, market status of the Retinal Pharmaceuticals on a global level that primarily aims the core...

VRX.TO : 30.80 (-3.33%)
BAYRY : 15.3740 (+1.61%)
SNPHF : 15.1500 (+2.02%)
NVS : 91.26 (-0.04%)
SHPG : 179.20 (+4.10%)
REGN : 305.81 (-0.27%)
Bacterial Conjunctivitis Drugs Market is estimated to witness a CAGR of 2.1% during the forecast period 2018-2024. Key Players are Novartis, Valeant Pharmaceuticals International, Teva Pharmaceuticals, and Akron Inc. and Perrigo Corporation,

Overview: Bacterial conjunctivitis is a contagious eye infection in which the conjunctiva of one or both the eyes are infected by bacteria such as Staphylococci, Gonococci, Chlamydia, and Streptococci....

VRX.TO : 30.80 (-3.33%)
BAYRY : 15.3740 (+1.61%)
MRK : 84.82 (+0.39%)
NVS : 91.26 (-0.04%)
SHPG : 179.20 (+4.10%)
CENTOGENE Announces the Appointment of Dr. Flemming Ornskov to the Supervisory Board as Non-Executive Chairman

ROSTOCK/BERLIN, GERMANY / ACCESSWIRE / April 2, 2019 / CENTOGENE announced today that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His appointment...

SHPG : 179.20 (+4.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade SHPG with:

Business Summary

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

See More

Key Turning Points

2nd Resistance Point 184.22
1st Resistance Point 181.71
Last Price 179.20
1st Support Level 176.20
2nd Support Level 173.20

See More

52-Week High 182.47
Last Price 179.20
Fibonacci 61.8% 160.03
Fibonacci 50% 153.10
Fibonacci 38.2% 146.17
52-Week Low 123.73

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar